186 related articles for article (PubMed ID: 30887140)
1. Highly Soluble Glimepiride and Irbesartan Co-amorphous Formulation with Potential Application in Combination Therapy.
Cruz-Angeles J; Videa M; Martínez LM
AAPS PharmSciTech; 2019 Mar; 20(4):144. PubMed ID: 30887140
[TBL] [Abstract][Full Text] [Related]
2. Characterization and therapeutic efficacy evaluation of glimepiride and L-arginine co-amorphous formulation prepared by supercritical antisolvent process: Influence of molar ratio and preparation methods.
Park H; Jin Seo H; Hong SH; Ha ES; Lee S; Kim JS; Baek IH; Kim MS; Hwang SJ
Int J Pharm; 2020 May; 581():119232. PubMed ID: 32240805
[TBL] [Abstract][Full Text] [Related]
3. Determination of the interaction between glimepiride and hyperbranched polymers in solid dispersions.
Pahovnik D; Reven S; Grdadolnik J; Borštnar R; Mavri J; Zagar E
J Pharm Sci; 2011 Nov; 100(11):4700-9. PubMed ID: 21656768
[TBL] [Abstract][Full Text] [Related]
4. A discriminating dissolution method for glimepiride polymorphs.
Bonfilio R; Pires SA; Ferreira LM; de Almeida AE; Doriguetto AC; de Araújo MB; Salgado HR
J Pharm Sci; 2012 Feb; 101(2):794-804. PubMed ID: 22052673
[TBL] [Abstract][Full Text] [Related]
5. Hyperbranched poly(esteramides) as solubility enhancers for poorly water-soluble drug glimepiride.
Reven S; Grdadolnik J; Kristl J; Zagar E
Int J Pharm; 2010 Aug; 396(1-2):119-26. PubMed ID: 20600725
[TBL] [Abstract][Full Text] [Related]
6. Solubility, dissolution rate and bioavailability enhancement of irbesartan by solid dispersion technique.
Boghra RJ; Kothawade PC; Belgamwar VS; Nerkar PP; Tekade AR; Surana SJ
Chem Pharm Bull (Tokyo); 2011; 59(4):438-41. PubMed ID: 21467670
[TBL] [Abstract][Full Text] [Related]
7. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
[TBL] [Abstract][Full Text] [Related]
8. Co-Amorphous Simvastatin-Nifedipine with Enhanced Solubility for Possible Use in Combination Therapy of Hypertension and Hypercholesterolemia.
Martínez-Jiménez C; Cruz-Angeles J; Videa M; Martínez LM
Molecules; 2018 Aug; 23(9):. PubMed ID: 30154310
[TBL] [Abstract][Full Text] [Related]
9. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
[TBL] [Abstract][Full Text] [Related]
10. Co-amorphous formulation of dipyridamole with p-hydroxybenzoic acid: Underlying molecular mechanisms, physical stability, dissolution behavior and pharmacokinetic study.
Guo W; Dong X; Li Y; Li C; Tian Y; Gao H; Li T; Zhu H; Wang J; Yang C
Eur J Pharm Biopharm; 2023 Mar; 184():139-149. PubMed ID: 36709922
[TBL] [Abstract][Full Text] [Related]
11. Development and Characterization of Microstructured, Spray-Dried Co-Amorphous Mixture of Antidiabetic Agents Stabilized by Silicate.
Wairkar S; Gaud R
AAPS PharmSciTech; 2019 Mar; 20(3):141. PubMed ID: 30868308
[TBL] [Abstract][Full Text] [Related]
12. Preparation and characterization of co-amorphous Ritonavir-Indomethacin systems by solvent evaporation technique: improved dissolution behavior and physical stability without evidence of intermolecular interactions.
Dengale SJ; Ranjan OP; Hussen SS; Krishna BS; Musmade PB; Gautham Shenoy G; Bhat K
Eur J Pharm Sci; 2014 Oct; 62():57-64. PubMed ID: 24878386
[TBL] [Abstract][Full Text] [Related]
13. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone.
Caron V; Tajber L; Corrigan OI; Healy AM
Mol Pharm; 2011 Apr; 8(2):532-42. PubMed ID: 21323367
[TBL] [Abstract][Full Text] [Related]
14. Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan.
Huang Y; Zhang Q; Wang JR; Lin KL; Mei X
Pharm Dev Technol; 2017 Feb; 22(1):69-76. PubMed ID: 27050301
[TBL] [Abstract][Full Text] [Related]
15. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
16. Study of glimepiride-b-cyclodextrin complex.
Moyano JR; Ventriglia T; Ginés JM; Muñoz F; Rabasco AM
Boll Chim Farm; 2003 Nov; 142(9):390-5. PubMed ID: 14971307
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Solid Dispersion of Itraconazole Prepared by Solubilization in Concentrated Aqueous Solutions of Weak Organic Acids and Drying.
Parikh T; Sandhu HK; Talele TT; Serajuddin AT
Pharm Res; 2016 Jun; 33(6):1456-71. PubMed ID: 26951566
[TBL] [Abstract][Full Text] [Related]
18. Study of the amorphous glibenclamide drug: analysis of the molecular dynamics of quenched and cryomilled material.
Wojnarowska Z; Grzybowska K; Adrjanowicz K; Kaminski K; Paluch M; Hawelek L; Wrzalik R; Dulski M; Sawicki W; Mazgalski J; Tukalska A; Bieg T
Mol Pharm; 2010 Oct; 7(5):1692-707. PubMed ID: 20669906
[TBL] [Abstract][Full Text] [Related]
19. Incorporation of Complexation into a Coamorphous System Dramatically Enhances Dissolution and Eliminates Gelation of Amorphous Lurasidone Hydrochloride.
Heng W; Su M; Cheng H; Shen P; Liang S; Zhang L; Wei Y; Gao Y; Zhang J; Qian S
Mol Pharm; 2020 Jan; 17(1):84-97. PubMed ID: 31794225
[TBL] [Abstract][Full Text] [Related]
20. Formulation and biological evaluation of glimepiride-cyclodextrin-polymer systems.
Ammar HO; Salama HA; Ghorab M; Mahmoud AA
Int J Pharm; 2006 Feb; 309(1-2):129-38. PubMed ID: 16377107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
